RxDoctor Payments DataLook up a doctor →

Fares Khater, MD

Internal Medicine · Whitesburg, KYNPI 1992732101

Payments from drug & device makers

$411,628in general payments, 2019–2025

Across 750 payments — averaging $548.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$185K
  • AbbVie$128K
  • Melinta Therapeutics, LLC$37K
  • Paratek Pharmaceuticals, Inc.$33K
  • La Jolla Pharmaceutical Company$27K
  • Orasure Technologies Inc.$1K
  • plus $567 from 10 others

What the payments were for

  • Consulting fees$24,9506%
  • Speaking & faculty fees$328,32380%
  • Travel & lodging$44,24511%
  • Food & beverage$13,9923%
  • Education$1200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$411,628 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$65,282
Medicare patients
227
Services billed
1,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir11$87,163
BiktarvyBictegrav/Emtricit/Tenofov Ala18$70,012
ArexvyRsvpref3 Antigen/As01e/Pf221$63,955
ShingrixVaricella-Zoster Ge/As01b/Pf241$50,053
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,022
FarxigaDapagliflozin Propanediol58$39,935
TriumeqAbacavir/Dolutegravir/Lamivudi11$38,749
TrulicityDulaglutide32$31,307
EliquisApixaban24$24,069
Darunavir16$22,205
JanuviaSitagliptin Phosphate38$21,053
OzempicSemaglutide14$19,299
JardianceEmpagliflozin17$15,813
Incruse ElliptaUmeclidinium Bromide13$4,526
Novolog FlexpenInsulin Aspart16$3,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$185,270$118,03430 claims
Lilly USA, LLCTrulicity$17$31,30732 claims
MerckJanuvia$37$21,05338 claims
Novo NordiskOzempic$94$19,29914 claims
Boehringer IngelheimJardiance$110$15,81317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Whitesburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →